Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 21, 2006

Cardinal Health Inks Cell Line Development Deal with Wyeth

  • Cardinal Health entered a feasibility agreement with Wyeth to develop cell lines using Cardinal Health’s Gene Product Expression (GPEx®) cell line engineering technology.

    Cardinal Health will use the technology to engineer cell lines that express two undisclosed biopharmaceutical molecules in experiments that will determine if the GPEx approach is a feasible augmentation to Wyeth’s current production methods.

    In addition to enabling rapid cell line development and availability of candidate gene products, the GPEx technology is “well suited for both efficient pilot and large-scale production of antibodies and other therapeutic recombinant proteins,” notes Paul Weiss, Ph.D., president of Cardinal Health’s biopharmaceutical development services center.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »